- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06759662
Association of Neutrophil- Lymphocyte Count Ratio and Microbial Infection in Hospitalized Patients
Microbial infection is one of leading cause of morbidity and mortality in the world. Bacteremia that result from microbial infection has mortality rate as high as 30% . Systemic infections that result from microbial infection is a generalized disease that progresses rapidly and can lead to high mortality. This infection sets in from a progression of various pathogenic microorganisms that enter the bloodstream, reproduce and then release toxins and metabolites . Early diagnosis of microbial infection is essential for treatment. Culturing microorganisms is the most definitive way to confirm bacterial infections. Unfortunately, this gold standard is time consuming and may take from 24 to 48 hours and sometimes up to a week. A number of rapid initial indicators of microbial infection have been proposed, including C-reactive protein, neutrophil count, and white blood cell count. However, these criteria do not always reliably distinguish between severe bacterial, fungal, and viral infections . Therefore, the neutrophil-to-lymphocyte ratio (NLCR), a simple ratio between the number of neutrophils and lymphocytes measured in peripheral blood, has been proposed as a biomarker that combines two aspects of the immune system: the innate immune response, which is mainly driven by neutrophils, and adaptive immunity, supported by lymphocytes . This study aims to determine the diagnostic value of the neutrophil-to-lymphocyte ratio (NLCR) as an indicator of microbial infection, using complete blood count to determine the ratio in addition to culture and sensitivity according to the site of infection.
the aim of this study is to Investigating the association between neutrophil-lymphocyte count and the presence of microbial infection in the hospitalized patients.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Asmaa Hamed Abdelwahed Mohamed, residant doctor
- Phone Number: +201019844307
- Email: asmaa26hamed@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- age more than 18 years old
- both sex
- conformed diagnosis with micorbial infection
Exclusion Criteria:
- Immunodeficiency patients
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
microbial infections cases
All cases diagnosed with microbial infections at Assiut university hospitals
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
neutrophil-lymphocyte count ratio
Time Frame: baseline
|
neutrophil-lymphocyte count ratio in the hospitalized patients with microbial infection
|
baseline
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- N-L count ratio microbial inf
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.